EFG
CTMX icon

Ethos Financial Group’s CytomX Therapeutics CTMX Stock Holding History

Ethos Financial Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,697
Closed -$101K – 650
2026
Q1 		$101K Hold
23,697
– – 0.01% 516
2025
Q4 		$101K Hold
23,697
– – 0.01% 505
2025
Q3 		$75.6K Buy
+23,697
New +$53.4K 0.01% 489

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Ethos Financial Group's CTMX Position: Q2 2026 in Review

Ethos Financial Group sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 23,697 shares — an estimated $101K sold.

Ethos Financial Group first reported a position in CTMX in Q3 2025 and held it in 3 quarters. The position peaked at $101K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Ethos Financial Group reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ethos Financial Group sold 23,697 CytomX Therapeutics shares in Q2 2026, an estimated $101K.
  • Ethos Financial Group first reported a position in CytomX Therapeutics in Q3 2025 and held it in 3 quarters.
  • Ethos Financial Group's CytomX Therapeutics position peaked at $101K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.